

Review Article

Pitfalls in Oncocardiology

Tamás Kullmann^{1*}, Nikolett Révész², Adél Ambrus¹, Dóra Füzi¹, Tamás Pintér¹, Csaba András Dézsi³

¹Department of Oncoradiology, Petz Aladár County Teaching Hospital, Győr, Hungary

²Department of Pulmonology, Petz Aladár County Teaching Hospital, Győr, Hungary

³Department of Cardiology, Petz Aladár County Teaching Hospital, Győr, Hungary

***Corresponding Author:** Tamás Kullmann, Department of Oncoradiology, Petz Aladár County Teaching Hospital, 9024 Győr, Vasvári Pál str. 2-4. Hungary, Tel: +3696418244; E-mail: kullmandoki@hotmail.com

Received: 24 February 2020; **Accepted:** 26 March 2020; **Published:** 03 April 2020

Citation: Tamás Kullmann, Nikolett Révész, Adél Ambrus, Dóra Füzi, Tamás Pintér, Csaba András Dézsi. Pitfalls in Oncocardiology. Journal of Cancer Science and Clinical Therapeutics 4 (2020): 086-090.

Abstract

Background: Onco-cardiology is a developing interdisciplinary field aiming to help oncologists to cope with the cardiovascular complications and comorbidities of patients followed for malignancies. Side effects of cytotoxic chemotherapies and targeted treatments are put into focus.

Methods: We selected from our database the most frequent cardiovascular complication and three cases that we found especially relevant from a clinical point of view.

Results: The establishment of the diagnosis of diastolic heart failure on a clinical basis is pointed out. The management of aortic valvulopathy, radiogenic myocarditis and a drug-induced conduction disorder is discussed.

Conclusions: The sensitisation of the oncologists to the evaluation of the cardiac status of their patients by their own is emphasised. Diastolic heart failure should be considered for cancer patients developing dyspnoea. The replacement of stenotic aortic valve should be considered for cancer patients with favourable prognosis.

Keywords: Oncocardiology; Aortic Stenosis; Myocarditis; Anthracycline; Vinorelbine; Cardiac Arrest

1. Introduction

Cardiovascular events and malignancies are leading causes of death worldwide. Smoking and obesity are common risk factors for both morbidities. Nevertheless, cardiac and vascular malignancies as well as losing a cancer patient of

acute coronary syndrome or stroke happen rarely. Oncocardiology is an interdisciplinary field helping oncologists to cope with cardiovascular complications, such as hypertension, coronary artery disease, arrhythmias, valvular heart disease, heart failure and venous thromboembolism [1]. According to a recent publication, taking into account the above conditions excepted hypertension, atrial fibrillation was the highest prevalent cardiovascular disease in cancer patients (4% in men and 1% in women) and the prevalence of all cardiovascular diseases increased progressively with age (12% in men and 7.5% in women over the age of 80) [2]. Cardiac complications or comorbidities may sometimes be life threatening. However, the possibility that a cancer patient be lost of another cause than his malignancy is not sufficiently taken into account. This paper reports a common and three rare situations when vital prognosis of cancer patients can be engaged by cardiac

comorbidities or complications, including diastolic heart failure, aortic valvulopathy, radiogenic myocarditis, and drug-induced conduction disorder.

2. Diastolic Heart Failure

Although shortness of breath is one of the leading complications of cancer patients, there are no studies to systematically investigate the epidemiology and the impact of dyspnoea on the outcome [3]. The potential causes of dyspnoea are summarised in Table 1. The most frequent cause of dyspnoea is left ventricular failure. Hence, iatrogenic hyperhydration and parenteral nutrition may aggravate subclinical cardiac failure. However, the evaluation of the diastolic function by echocardiography is problematic. The ejection fraction being in the correct range does not rule out the possibility of diastolic heart failure.

Cardiovascular
Left ventricular heart failure
Pulmonary embolism
Tumoral compression of the pulmonary artery
Respiratory
Pneumonia
Pleural effusion
Atelectasis
Carcinomatous lymphangitis
Multiple pulmonary metastases
Laryngeal occlusion
Haematological
Anaemia
Psychological
Anxiety

Table 1: Causes of shortness of breath in patients followed for a malignancy.

Indeed, up to the half of all heart failures may be of diastolic origin [4]. These patients typically develop dyspnoea during hospitalisation still physicians may fail to consider the prescribed treatment as a source of their symptoms. The presence of orthopnoea is an important anamnestic element of orientation. The favourable response to diuretic treatment or to the decrease of intravenous

volume administration may confirm the hypothesis and sometimes even be lifesaving. Since the cumulative limits of 450 mg for adriamycine and 900 mg for epirubicine have been respected, chemotherapy induced systolic heart failure has had less clinical impact [5]. Docetaxel and trastuzumab induced systolic cardiac failure is usually reversible [6] (Table 2).

Drug	Cardiovascular side effect
anthracyclines	heart failure +++
docetaxel	heart failure ++
trastuzumab	heart failure +
5-fluoro-uracil	coronary spasm
LHRH agonists	arrhythmia
bevacizumab	hypertension
sunitinib	hypertension
axitinib	hypertension
pazopanib	hypertension
sorafenib	hypertension

Table 2: The most frequent cardiovascular toxicities of anticancer agents.

3. Valvulopathy

A 70-year-old male patient was treated with adjuvant chemotherapy, following resection of a non-metastatic sigmoid colic cancer (adenocarcinoma, grade 1, 0N+/3N). He had a history of type 2 diabetes, hypertension, ischaemic heart disease, CABG intervention, aortic stenosis with a systolic gradient of 20 mmHg, dominant hemispheric TIA and contralateral carotid endarterectomy. A 4/6 ejection murmur was detected on the initial physical examination. The patient did not report any chest pain or dyspnoea. Before the 11th cycle of chemotherapy he had a loss of consciousness upon an effort at home. Control echocardiography showed a systolic gradient of 80 mmHg. Aortic valve replacement was decided and a biologic valve was implanted 16 months after the removal of the colic

tumour. The patient is symptom free 3 years after the cardiac surgery. The control examinations including colonoscopy and CT scan did not show any sign of recurrence. Aortic stenosis is the clinically most important valvulopathy. In case it becomes symptomatic or the systolic gradient reaches 80 mmHg its replacement may be indicated even in case of comorbidities. According to a survey a quarter of metastatic cancer patients having severe aortic stenosis were lost because of cardiac complications and not the progression of their malignancy [7]. On the other hand, the presence of a cancer does not raise the risk of valve replacement as compared to patients without malignant disease [8]. For our patient it took several months until the decision was finally done. His favourable cancer-free prognosis was taken into account. The choice of a

biologic valve allowing the skipping of anticoagulant treatment would guarantee more safety even in case of local recurrence.

4. Myocarditis

A 55-year-old male patient was treated by palliative chemotherapy for right sided central small-cell lung cancer. The treatment was completed by radiotherapy. He had a history of myocardial infarction and coronary stent implantation. Constricting retrosternal pain occurred after the delivery of 24 Gy. The ECG showed elevated ST segments in the infero-lateral regions (Figure 1). Emergency echocardiography did not show pericardial effusion, coronarography did not detect any significant

stenosis. The diagnosis of radiogenic myocarditis was retained. The patient's complaints and ECG alterations disappeared after stopping radiotherapy. He was lost 6 months later for cerebral progression of the pulmonary malignancy. Radiogenic myocarditis was a more frequent complication of radiotherapy before the era of conformational radiotherapy. We retrospectively verified the planning of our patient and less than 20% of the heart was exposed to a maximal dose of 28 Gy, nevertheless the infero-lateral region received a relatively higher dose. This planning was prepared during the learning period after the installation of a conformational linear accelerator at our department.




Figure 1: ECG showing elevation of the ST segments in non-related derivations, compatible with myocarditis.

5. Atrioventricular Block

A 64-year-old female patient was diagnosed thirteen months earlier with cT4N1M0, hormone sensitive left sided mammal carcinoma (CDI, ER+, PR+, HER2-, Mib1:10%). She progressed after 12 months of letrozole and immediately after the first injection of fulvestrant. She refused the proposed intravenous chemotherapy. Due to the local extension of the disease the realisation of a hygienic mastectomy was not possible. Oral chemotherapy by vinorelbine was offered and finally accepted by the patient. An asymptomatic bradycardia with a ventricular rhythm

around 40/min was noticed in the days following introduction of vinorelbine by blood pressure auto-measuring. An ECG was realised before the 4th weekly dose and showed 3rd degree atrio-ventricular block (Figure 2). The patient was authorised to take the 4th dose of vinorelbine. The next morning she had a cardiac arrest at home. Drug induced conduction disorder has not yet been described with vinorelbine. The stopping of the β -antagonist taken for years proposed by the cardiology consultation did not prevent the fatal outcome.




Figure 2: ECG showing 3rd degree atrio-ventricular block.

6. Conclusions

The sensitisation of the oncologists to the evaluation of the cardiac status of their patients by their own is emphasised. Diastolic heart failure should be considered for cancer patients developing dyspnoea. The replacement of stenotic aortic valve should be considered for cancer patients with favourable prognosis.

Conflict of Interest

The authors declare having no conflict of interest in connection with the publication of this paper.

References

1. Totzeck M, Schuler M, Stuschke M, et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. *Int J Cardiol* 280 (2019): 163-175.
2. Okura Y, Takayama T, Ozaki K, et al. Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City. *Int J Clin Oncol* 24 (2019): 196-210.
3. Meriggi F. Dyspnea in Cancer Patients: A Well-Known and Neglected Symptom. *Rev Recent Clin Trials* 13 (2018): 84-88.
4. Røe ÅT, Sjaastad I, Louch WE. Heart failure with preserved ejection fraction. *Tidsskr Nor Laegeforen* 137 (2017).
5. Trédaniel J. Les médicaments du cancer. Groupe CFI-ZI Petite Montagne Sud, Évry, (2009).
6. Fogarassy G, Vathy-Fogarassy Á, Kenessey I, et al. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis. *Int J Cardiol* 285 (2019): 47-52.
7. Okura Y, Ishigaki S, Sakakibara S, et al. Prognosis of Cancer Patients with Aortic Stenosis Under Optimal Cancer Therapies and Conservative Cardiac Treatments. *Int Heart J* 59 (2018): 750-758.
8. Mangner N, Woitek FJ, Haussig S, et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. *J Interv Cardiol* 31 (2018): 188-196.



This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC-BY\) license 4.0](https://creativecommons.org/licenses/by/4.0/)